Lanreotide

FDA-approved product existsPeptideGH axis & hormones

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Lanreotide?

FDA-approved lanreotide products exist for long-term treatment of acromegaly and for specified gastroenteropancreatic neuroendocrine tumors.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelLanreotide injection prescribing information for acromegaly, GEP-NETs, and carcinoid syndrome
PopulationAdults covered by the approved lanreotide indications
DoseAcromegaly starts at 90 mg every 4 weeks for 3 months before response-based adjustment. GEP-NET and carcinoid-syndrome dosing is 120 mg every 4 weeks.
RouteDeep subcutaneous injection in the superior external quadrant of the buttock by a healthcare provider
FrequencyEvery 4 weeks
DurationLong-term use within the approved indication with label-directed monitoring
PreparationReady-to-use single-dose prefilled syringes containing 60 mg/0.2 mL, 90 mg/0.3 mL, or 120 mg/0.5 mL; no reconstitution.
Source: Dosage and Administration sections 2.1-2.4; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA-approved products exist; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.